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SUMMARY  
 
Pemphigus vulgaris (PV) is an autoimmune blistering disease produced by IgG 
autoantibodies against desmoglein (Dsg)3. Lesions on the skin and mucosa can, in rare 
cases, be induced by radiotherapy. We report a patient with a history of 
microprolactinoma and PV, who had only oral lesions from the beginning of her illness 
but 2 months after treatment with radiotherapy for a breast neoplasia, developed skin 
lesions limited to the irradiated area. Over the following few months, she also 
developed autoantibodies against Dsg1. 
 
 
Pemphigus vulgaris (PV) is a blistering disease produced by IgG autoantibodies, which 
bind mainly to desmoglein (Dsg)3. It can be induced by many triggers including drugs, 
burns, nutritional factors, herpes virus, contact dermatitis, emotional stress and 
ultraviolet radiation.1 Although rare, ionizing radiation treatment can also induce PV.2–7 
 
 
REPORT 
 
A 39-year-old woman presented to our centre in 1999 with a 7-month history of 
amenorrhoea. She reported no headache, visual field reduction or spontaneous 
galactorrhoea. Laboratory investigations found a raised serum prolactin level (106.3 
ng⁄mL; normal range 1.4–24). Magnetic resonance imaging (MRI) of the brain using 
paramagnetic contrast revealed a hypophyseal microadenoma. The patient was started 
on treatment with a dopaminergic agonist (cabergoline). 
 
In 2000, patient developed dysphagia, dysphonia and erosions in the mouth. 
Histological examination of a biopsy taken from an erosion revealed an intraepidermal 
suprabasilar blister with acantholysis. Direct immunofluorescence (DIF) using total IgG 
(IgGT) showed intense deposits of IgG and C3 on the cell surface of the keratinocytes. 
Indirect immunofluorescence (IIF) found circulating antiepithelial cell surface IgG (titre 
1 : 80). Using ELISA (MBL Naka-ku Nagoya, Japan), anti-Dsg3 antibodies (48 U⁄mL; 
normal range 0 – 20) were found, but there were no anti-Dsg1 antibodies. Fibroscopy 
revealed lesions on the pharynx and larynx. The patient was diagnosed with a mucosal-
dominant PV. A few days after beginning treatment, she also presented lesions on the 
back, right ear and nose (the number of cutaneous lesions was < 5, so her illness was 
still considered mucosal-dominant PV).8 
 
Over the next 6 years, the patient had occasional oral lesions (Fig. 1a) but no cutaneous 
lesions. In 2002, she developed new oral lesions while she was being treated with 
azathioprine and low-dose corticosteroids. Azathioprine was changed to mycophenolic 
acid. In 2003, oral corticosteroids were discontinued, and in 2005, mycophenolic acid 
was discontinued. The patient was advised to use topical triamcinolone acetonide if she 
developed oral lesions. 
 
In 2006, the patient was diagnosed with an intraductal carcinoma type II of the breast 
(negative for p53 and C-erb-2, 100% positive for oestrogen and progesterone, positive 
for E-cadherin; Van Nuys Prognostic Index 7; TisN0M0). She underwent conservative 
surgery and radiotherapy for 2 months. Fractions of 2 Gy, using 6 MeV photons, were 
given daily until a total dose of 50 Gy was reached. The scar and the surgical bed were 
further treated using a direct field of electrons of 9 MeV, daily fractions of 2 Gy, until 
an additional dose of 16 Gy had been delivered to this site. During the radiotherapy, she 
continued being treated with cabergoline. 
 
Two months after finishing the radiotherapy, skin lesions suggestive of PV appeared on 
the irradiated breast (Fig. 1b), and the patient also presented oral lesions. IIF revealed 
no circulating antiepithelial cell surface IgGT. ELISA detected borderline levels of 
antiDsg3 antibodies (19.18 U⁄mL) and was also positive for anti-Dsg1 antibodies (26.96 
U⁄mL; normal range 0–20) (Table 1). One month later, the patient was still negative for 
circulating antiepithelial cell surface IgGT, anti-Dsg3 antibody levels were still 
borderline (15.60 U⁄mL) and anti-Dsg1 antibodies were again positive (22.20 U⁄mL) 
(Table 1). 
 
Currently, the patient continues to develop occasional lesions in the mouth and on the 
irradiated breast. She is negative for circulating antiepithelial cell surface IgGT, anti-
Dsg3 antibodies are borderline (15.38) and antiDsg1 antibodies are negative (Table 1). 
Restarting systemic treatment has not been suggested because of her history of breast 
neoplasia, and because the oral and the breast lesions are well controlled with topical 
corticosteroids. 
 
PV can be induced by the administration of radiotherapy.2–7 In previous reports, 
radiotherapy was used for the treatment of various neoplasms,4–6 and the time interval 
between the radiotherapy and the onset of the cutaneous lesions varied from a few days 
to > 1 year.4 
 
The explanation for this relationship between PV and radiotherapy is unclear. The 
ionizing radiation may alter the antigenicity of the surface of the keratinocytes, thus 
changing the immunoreactivity of the desmogleins or unmasking certain epidermal 
antigens.4,5 An increase in the concentration of the antibodies against the basement 
membrane may also be produced by radiotherapy.5 The existence in almost all cases of 
an underlying neoplasm raises the question as to the role that cancer and its treatment 
may play in the induction of PV.4,5 The immune disturbance produced by the neoplasm 
may contribute to development of PV.2 One hypothesis maintains that the cause may be 
a crossover between tumour and keratinocyte antigens. Another hypothesis suggests that 
an alteration in the regulation of the cell cycle may be the origin of both the tumoral 
proliferation and the defective elimination of auto-reactive lymphocyte clones. 
 
In our patient, the fact that for 6 years she had lesions exclusively on the oral mucosa, 
and that lesions appeared on the skin only after radiotherapy and then only on the 
radiated site, indicates that the radiotherapy itself induced the new lesions. This is 
further supported by the observation that over the months after the radiotherapy, the 
patient presented anti-Dsg1 antibodies. This was probably due to the ‘epitope-
spreading’ phenomenon;9 the tissue damage produced by the radiotherapy caused the 
release and exposure of a previously ‘sequestered’ antigen, leading to a secondary 
autoimmune response against this newly released antigen. 
 
Our patient had a hypophyseal prolactin-producing microadenoma, which probably 
favoured the growth of the breast neoplasm. Increases in prolactin may be a contributing 
factor for the appearance of the PV, as an increase in prolactin has been associated with 
the onset of various autoimmune illnesses.10 
 
The microadenoma was diagnosed with the help of MRI using paramagnetic contrast. A 
diagnostic process using an imaging agent can be the initial primer for the immune 
system, unleashing an immune response. However, we have found no published cases 
suggesting a relationship between pemphigus and the previous use of paramagnetic 
contrast. 
 
During the radiotherapy, our patient continued being treated with cabergoline. An 
immunological interaction between the radiation treatment and the immune 
dysregulation produced by the dopaminergic agonist is possible. 
 
We present this case to show that radiotherapy can induce lesions of PV. The case is 
also interesting because for a few months after receiving radiotherapy, our patient also 
presented autoantibodies against Dsg1. 
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Figure 1. Lesions (a) in the mouth and (b) on the breast. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Autoantibodies present the patient 
 
Autoantibody At start of illness 
March 
2006 August 2006 
September 
2006 November 2006
Antiepithelial cell 
surface IgG 
Positive (titre 
1:80) Negative Negative Negative Negative 
Anti-Dsg3 
antibodies 
Positive (48 U ⁄ 
mL) Negative 
Borderline (9.18 
U ⁄ mL) 
Borderline (5.60 
U ⁄ mL) 
Borderline 
(15.38 U ⁄ mL)
Anti-Dsg1 
antibodies Negative Negative 
Positive (26.96 
U ⁄ mL) 
Positive (22.20 
U ⁄ mL) Negative 
Dsg, desmoglein. Normal range for anti-Dsg1 and anti-Dsg3 antibodies: 0–20 U ⁄ mL. The patient 
received radiotherapy from 8 March to 27 April 2006. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
